Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Burkitt Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Down Syndrome 1

Interventions

Vincristine 5merphos 4Methotrexate 4Dexamethasone 4Cytarabine 4Cyclophosphamide 4pegaspargase 3dexamethasone acetate 3dexamethasone 21-phosphate 3blinatumomab 3azathiopurine 3auricularum 3Mercaptopurine 3Leucovorin 3Doxorubicin 3Calcium Dobesilate 3prednylidene 2deltacortene 2asparaginase erwinia chrysanthemi recombinant 2Thioguanine 2Spinal Puncture 2Specimen Handling 2Prednisone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Inotuzumab Ozogamicin 2Asparaginase 2venetoclax 1ofatumumab 1calaspargase pegol 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Asparaginase × 30 days × Clear all
NCT02981628 2026-06-05

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡